Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05177822 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart Failure

Study acronym: VA-ART4
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Recruiting → Active, Not Recruiting
    • Site details revised at 2 of 2 sites
    v12
  2. Primary completion date: Feb 28, 2027 to Feb 22, 2027
    • Study completion date: Dec 31, 2027 to Dec 30, 2027
    v11
  3. Primary completion date: Feb 2027 to Feb 28, 2027
    • Study completion date: Dec 2027 to Dec 31, 2027
    v10
  4. Re-verified, no change to tracked fieldsv9
  5. Site details revised at 2 of 2 sites
    • Collaborators: 1 to 2
    v8
Show 6 earlier versionsHide 6 earlier versions
  1. 2 versions Re-verified, no change to tracked fieldsv6-v7
  2. Eligibility criteria expanded, about 62 wordsv5
  3. Start date changed from estimate of Jun 2022 to May 24, 2022v4
  4. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Start date: Apr 2022 to Jun 2022
    • Study sites: 1 to 2
    • Eligibility criteria expanded, about 48 words
    • Collaborators expanded, about 5 words
  5. Start date: Jan 2022 to Apr 2022v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Patients who have a heart attack are at high risk for future development of heart failure ('weakening of the heart'). The researchers believe that the reaction of the heart muscle to injury (inflammation) during a heart attack may be contributing to the risk of heart failure. The current study will test the ability of an anti-inflammatory medicine (anakinra) to block the inflammation in the body during and after a heart attack.
Trial Details
NCT Number NCT05177822
Lead Sponsor Virginia Commonwealth University
Collaborators: National Institute on Aging (NIA), University of Virginia
Conditions
(from sponsor)		 Heart Failure
Related terms Heart Failure
Enrollment 84 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov